Using riociguat in patients with PAH and cardiometabolic comorbidities: JHLT: The Podcast
Published 18 March 2025
The JHLT Digital Media Editors met this month for a discussion on the paper, "Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials.”
You can also stream the podcast on Spotify, Amazon, iTunes, and anywhere else you get podcasts.
The episode explores:
- The aging PAH population and the new comorbidities that must be considered in research
- How the study augments and expands on recent standards, like the 2022 ESC/ERS guidelines for pulmonary hypertension
- Limitations on the study and opportunities for future research
For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you’re an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.
Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.